The FDA just approved the first mRNA-based flu vaccine for Americans 50 and older — expanding the same platform rushed to market during COVID before long-term safety data existed, and greenlighting it for seniors under an accelerated pathway that makes the public the post-market study.
Moderna's mFlusiva won full approval for adults 50 to 64 based on a 40,000-person trial that found it reduced flu cases by roughly 27% compared with a standard flu shot. But for adults 65 and older — the population most vulnerable to influenza — the FDA granted only accelerated approval, based on a smaller study showing a strong immune response rather than actual disease reduction. The company must conduct an additional postmarketing study. In plain English: regulators are letting Moderna sell it to seniors now and verify the results later.
Moderna's own data showed no major safety issues, but side effects — injection site pain, fever, headache, fatigue, muscle aches — occurred somewhat more frequently than with existing flu shots. CNN reported the side effects also included swollen lymph nodes, nausea, and vomiting.
The approval didn't come without a fight inside the agency. Earlier this year, a top FDA official blocked Moderna's application — a sign, as both the Guardian and AP reported, of the heightened vaccine scrutiny under Health Secretary Robert F. Kennedy Jr. Days later, the FDA reversed course after Moderna publicly challenged the ruling. In June, a panel of independent advisers to the FDA unanimously recommended approval.
The internal FDA reversal raises the obvious question: what changed in two weeks? The data didn't. What changed was political pressure from a pharmaceutical company that publicly challenged its regulator — and won.
CNN framed the approval against a contradictory policy backdrop: the Trump administration withdrew support for mRNA infectious-disease research, with HHS canceling some $500 million in mRNA projects in August 2025. Kennedy claimed at the time that mRNA vaccines "fail to protect effectively against upper respiratory infections like COVID and flu." Yet his own agency just approved one for flu.
Meanwhile, the CDC's Advisory Committee on Immunization Practices — which normally reviews data and recommends whether a new vaccine should be used — hasn't met since Kennedy replaced all its members. A federal judge ruled in March that Kennedy didn't follow federal legal procedures in doing so. The committee's next meeting isn't scheduled until October, meaning mFlusiva hits pharmacy shelves without the standard CDC recommendation process.
Moderna CEO Stéphane Bancel called the approval evidence of "the ongoing potential of our mRNA platform." Moderna says it expects the shot at select retailers this fall.
The same company, the same technology, the same regulatory shortcuts — only this time it's the flu, and the oldest Americans get the least rigorous approval pathway. The postmarket study will eventually tell us what the premarket data couldn't. The question is who volunteers for that experiment, and whether they know they're in it.
